Coherus Biosciences announced “positive topline 24-week treatment phase three results” in patients with psoriasis for CHS-1420, its proposed biosimilar to Humira® (adalimumab). Coherus stated that it anticipates filing its Biologic License Application (BLA) in the first half of 2017.
Coherus previously reported positive topline results from this ongoing trial, and indicated that it is planning to launch the product in 2018.